SK282491B6 - Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents

Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie Download PDF

Info

Publication number
SK282491B6
SK282491B6 SK504-96A SK50496A SK282491B6 SK 282491 B6 SK282491 B6 SK 282491B6 SK 50496 A SK50496 A SK 50496A SK 282491 B6 SK282491 B6 SK 282491B6
Authority
SK
Slovakia
Prior art keywords
chloro
quinoline
hydroxy
dione
tetrahydropyridazino
Prior art date
Application number
SK504-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK50496A3 (en
Inventor
Thomas Michael Bare
Richard Bruce Sparks
James Roy Empfield
Timothy Wayne Davenport
Jeffrey Alan Mckinney
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of SK50496A3 publication Critical patent/SK50496A3/sk
Publication of SK282491B6 publication Critical patent/SK282491B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK504-96A 1993-10-22 1994-10-20 Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie SK282491B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds
PCT/GB1994/002295 WO1995011244A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Publications (2)

Publication Number Publication Date
SK50496A3 SK50496A3 (en) 1997-03-05
SK282491B6 true SK282491B6 (sk) 2002-02-05

Family

ID=26303731

Family Applications (1)

Application Number Title Priority Date Filing Date
SK504-96A SK282491B6 (sk) 1993-10-22 1994-10-20 Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie

Country Status (30)

Country Link
US (3) US5744471A (xx)
EP (2) EP0724583B1 (xx)
JP (1) JP3583132B2 (xx)
KR (1) KR100261209B1 (xx)
CN (1) CN1053189C (xx)
AT (2) ATE295846T1 (xx)
AU (2) AU688393B2 (xx)
CA (1) CA2171332A1 (xx)
CZ (1) CZ292311B6 (xx)
DE (2) DE69434380T2 (xx)
DK (2) DK1004582T3 (xx)
ES (2) ES2241513T3 (xx)
FI (2) FI113865B (xx)
GB (1) GB9420590D0 (xx)
GR (1) GR3035080T3 (xx)
HK (1) HK1013997A1 (xx)
HU (1) HUT74161A (xx)
IL (1) IL111266A (xx)
MY (2) MY124316A (xx)
NO (1) NO306995B1 (xx)
NZ (2) NZ275472A (xx)
PL (1) PL180679B1 (xx)
PT (2) PT724583E (xx)
RU (1) RU2168511C2 (xx)
SG (2) SG59971A1 (xx)
SI (2) SI1004582T1 (xx)
SK (1) SK282491B6 (xx)
TW (1) TW406082B (xx)
UA (1) UA60291C2 (xx)
WO (1) WO1995011244A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
WO2001047524A1 (en) * 1999-12-23 2001-07-05 Astrazeneca Ab Method and composition for the treatment of pain
NZ519390A (en) * 1999-12-23 2003-07-25 Astrazeneca Ab 7-Chloro-4-hydroxy-2-(2-chloro-4-methylphenyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione useful for treating pain
EP1577311A1 (en) * 1999-12-23 2005-09-21 AstraZeneca AB Salts of a pyridazino aquinoline derivative and use for the treatment of pain
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
KR20020062983A (ko) * 1999-12-23 2002-07-31 아스트라제네카 아베 통증의 치료 방법 및 조성물
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
JP2003519148A (ja) * 1999-12-23 2003-06-17 アストラゼネカ・アクチエボラーグ 痛みの処置のための化合物および方法
JP2003519145A (ja) * 1999-12-23 2003-06-17 アストラゼネカ・アクチエボラーグ 痛みの処置のための化合物および方法
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
DE60026883T2 (de) * 1999-12-23 2006-11-23 Astrazeneca Ab Methoden und zusammensetzungen zur behandlung von schmerzen
EP1244664A1 (en) * 1999-12-23 2002-10-02 AstraZeneca AB Compounds and methods for the treatment of pain
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
WO2002026738A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
ATE334982T1 (de) * 2000-09-29 2006-08-15 Astrazeneca Ab 7-chlor-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-
AU2001292500A1 (en) * 2000-09-29 2002-04-08 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
WO2002026739A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
RU2278112C2 (ru) * 2001-05-31 2006-06-20 Санофи-Авентис Производные аминохинолина и аминопиридина и их применение в качестве лигандов аденозина a3
WO2005012309A1 (en) * 2003-08-04 2005-02-10 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
DK1773816T3 (en) 2004-06-24 2015-01-26 Vertex Pharma Modulators of ATP-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
NZ624460A (en) 2009-03-20 2015-12-24 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
ATE295846T1 (de) 2005-06-15
AU7944094A (en) 1995-05-08
EP0724583A1 (en) 1996-08-07
NO961584D0 (no) 1996-04-19
CZ292311B6 (cs) 2003-09-17
SG92630A1 (en) 2002-11-19
US6103721A (en) 2000-08-15
UA60291C2 (uk) 2003-10-15
ES2154686T3 (es) 2001-04-16
SK50496A3 (en) 1997-03-05
IL111266A (en) 2002-03-10
DE69426422D1 (de) 2001-01-18
HUT74161A (en) 1996-11-28
HK1013997A1 (en) 1999-09-17
SI1004582T1 (xx) 2005-08-31
EP0724583B1 (en) 2000-12-13
CZ113896A3 (en) 1996-09-11
ATE198072T1 (de) 2000-12-15
AU721139B2 (en) 2000-06-22
DE69434380T2 (de) 2006-05-04
DK0724583T3 (da) 2001-03-05
US5744471A (en) 1998-04-28
GR3035080T3 (en) 2001-03-30
ES2241513T3 (es) 2005-11-01
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
FI970907A0 (fi) 1997-03-03
FI961696A (fi) 1996-04-18
MY132875A (en) 2007-10-31
FI970907A (fi) 1997-03-03
NZ329303A (en) 2000-01-28
DE69426422T2 (de) 2001-05-10
NZ275472A (en) 1998-03-25
CN1138332A (zh) 1996-12-18
JP3583132B2 (ja) 2004-10-27
HU9600889D0 (en) 1996-06-28
IL111266A0 (en) 1994-12-29
MY124316A (en) 2006-06-30
CA2171332A1 (en) 1995-04-27
AU6899998A (en) 1998-07-30
KR100261209B1 (ko) 2000-09-01
FI114916B (fi) 2005-01-31
GB9420590D0 (en) 1994-11-30
RU2168511C2 (ru) 2001-06-10
PL180679B1 (en) 2001-03-30
FI113865B (fi) 2004-06-30
CN1053189C (zh) 2000-06-07
FI961696A0 (fi) 1996-04-18
DK1004582T3 (da) 2005-08-15
PT724583E (pt) 2001-03-30
AU688393B2 (en) 1998-03-12
DE69434380D1 (de) 2005-06-23
EP1004582A3 (en) 2000-08-30
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
SG59971A1 (en) 1999-02-22
JPH09504519A (ja) 1997-05-06
NO306995B1 (no) 2000-01-24
PL314041A1 (en) 1996-08-05
US6232313B1 (en) 2001-05-15
EP1004582B1 (en) 2005-05-18
WO1995011244A1 (en) 1995-04-27
EP1004582A2 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
SK282491B6 (sk) Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie
EP2922841B1 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US5475008A (en) Quinolone derivatives
US5837705A (en) Alpha-substituted pyridazino quinoline compounds
EP0115469B1 (de) Heterocyclisch ankondensierte Pyrazolo(3,4-d)pyridin-3-one
JP3279633B2 (ja) ピリダジンジオン化合物
WO2018139876A1 (ko) 신규한 [1, 2, 4] 트리아졸로 [4, 3-a]퀴녹살린 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 bet 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
WO2000040565A1 (en) Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors
AU705938B2 (en) Pyridazino quinoline compounds
US6214826B1 (en) Pyridazino quinoline compounds
RU2279432C2 (ru) Производные пиридазинохинолина
KR100295148B1 (ko) 피리다지노퀴놀린 화합물

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20091020